Press Releases Press Releases Year None20202019201820172016 Date Title July 6, 2020 UNITY Biotechnology Announces CFO Transition Lynne Sullivan appointed interim chief financial officer SAN FRANCISCO , July 06, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that July 1, 2020 UNITY Biotechnology, Inc. Provides Updates on Lead Development Programs – Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 – – First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 – SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. June 11, 2020 UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference SAN FRANCISCO , June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the May 7, 2020 UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March May 4, 2020 UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results SAN FRANCISCO , May 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020 UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101 – Topline 12- and 24-week results expected in 2H 2020 – SAN FRANCISCO , March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates March 30, 2020 UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants SOUTH SAN FRANCISCO, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. today announced that Anirvan Ghosh , Ph.D., has officially joined the company as Chief Executive Officer. As previously announced, Dr. Ghosh is a renowned scientist and drug development leader who joins UNITY March 11, 2020 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the fourth quarter and full March 3, 2020 UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results SAN FRANCISCO , March 03, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the fourth quarter and March 2, 2020 UNITY Biotechnology Appoints Anirvan Ghosh, Ph.D. as Chief Executive Officer – Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan – – Succeeds Keith Leonard Who Will Continue as Chairman – SAN FRANCISCO , March 02, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology today announced the appointment of Anirvan Ghosh , Ph.D., as CEO and member of the Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12
